NASDAQ:PRVL

Prevail Therapeutics (PRVL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$23.00
$23.00
50-Day Range
$22.91
$23.20
52-Week Range
$9.02
$23.35
Volume
N/A
Average Volume
955,800 shs
Market Capitalization
$787.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PRVL stock logo

About Prevail Therapeutics Stock (NASDAQ:PRVL)

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

PRVL Stock News Headlines

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Humanity must prevail in Gaza
Why Some Teams Fail And Others Prevail
See More Headlines
Receive PRVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2020
Today
4/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVL
CIK
N/A
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-63,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.85 per share

Miscellaneous

Free Float
N/A
Market Cap
$787.66 million
Optionable
Not Optionable
Beta
1.59
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Asa Abeliovich M.D. (Age 56)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $737.47k
  • Dr. Yong Dai Ph.D. (Age 49)
    Chief Technology Officer
    Comp: $450.62k
  • Dr. Jeffrey Sevigny M.D. (Age 51)
    Chief Medical Officer
    Comp: $593k
  • Dr. Brett Kaplan M.D. (Age 46)
    CFO & Sec.
  • Ms. Kira M. Schwartz
    Gen. Counsel
  • Ms. Emily Minkow (Age 37)
    Chief Bus. Officer
  • Dr. Franz F. Hefti Ph.D. (Age 72)
    Chief Devel. Officer

PRVL Stock Analysis - Frequently Asked Questions

How were Prevail Therapeutics' earnings last quarter?

Prevail Therapeutics Inc. (NASDAQ:PRVL) announced its earnings results on Friday, November, 13th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.09.

What other stocks do shareholders of Prevail Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Sorrento Therapeutics (SRNE), Alector (ALEC), Gossamer Bio (GOSS), Editas Medicine (EDIT), Harpoon Therapeutics (HARP), Atreca (BCEL), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO) and Stoke Therapeutics (STOK).

When did Prevail Therapeutics IPO?

Prevail Therapeutics (PRVL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

This page (NASDAQ:PRVL) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners